2024
PO0116 Design and Characterization of a Brachytherapy Applicator with Modulated Shielding (MOSH) for the Treatment of Cervical Cancer
Schwipper C, Mullane S, Draeger E, Chen Z, Rivard M, Tien C. PO0116 Design and Characterization of a Brachytherapy Applicator with Modulated Shielding (MOSH) for the Treatment of Cervical Cancer. Brachytherapy 2024, 23: s92. DOI: 10.1016/j.brachy.2024.08.134.Peer-Reviewed Original ResearchDose distributionBrachytherapy applicationsOAR dosesIr-192TG-43 dose calculation formalismShield geometryReduces dose to OARAAPM TG-43 formalismShielding materialsDose calculation formalismHigh-Z shieldingReduced OAR dosesCalculated dose distributionsTG-43 formalismDose-volume objectivesDose to OARsTreatment of cervical cancerHDR brachytherapy applicatorsHigh-risk clinical target volumeIr-192 sourceImproved dose distributionClinical target volumeSparing OARsTOPAS MCYb-169
2022
Single application hybrid interstitial brachytherapy for cervical cancer: an institutional approach during the COVID-19 pandemic
Damast S, Tien CJ, Young M, Altwerger G, Ratner E. Single application hybrid interstitial brachytherapy for cervical cancer: an institutional approach during the COVID-19 pandemic. Journal Of Contemporary Brachytherapy 2022, 14: 66-71. PMID: 35233237, PMCID: PMC8867238, DOI: 10.5114/jcb.2022.113058.Peer-Reviewed Original ResearchOverall treatment timeHR-CTV DCervical cancerMucosal toxicityMedian high-risk clinical target volumeHigh-risk clinical target volumeCOVID-19 pandemicLocal control outcomesPre-COVID cohortClinical target volumeMagnetic resonance imagingGastrointestinal eventsRetrospective reviewCC patientsEarly outcomesCOVID groupMedian numberInpatient resourcesInterstitial brachytherapyGrade 2Local controlResonance imagingSeparate weeksTarget volumePatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply